Brain tumor drug safety under scrutiny: temozolomide liver risk study launched
NCT ID NCT07675070
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at how safe and effective temozolomide (brand name Amitzo) is for people with aggressive brain tumors (grade III and IV gliomas). Researchers are tracking 100 patients to see how often liver injury occurs and to monitor other side effects. The goal is to better understand the risks of this chemotherapy drug in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- temozolomide (Amitzo)
- What this could lead to
- If successful, this study could confirm the safety profile of temozolomide for glioma patients, potentially guiding safer treatment protocols.
- What could go wrong
- This is an observational study with no control group, so results may not prove cause and effect. Liver injury is a known risk of temozolomide, and the study's small size limits general conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Orchid Pharmed
RECRUITINGTehran, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Digital tests may offer a new way to track brain health in tumor patients
- Mapping the hidden toll of brain radiation on young minds
- Scientists create detailed brain maps to protect language during surgery
- Could a cancer drug shrink recurrent brain tumors?
- Engineered immune cells target deadly brain tumors in children